Form 4: P&G Director Rajesh Subramaniam Receives Stock Award
Insider Transaction Report
Procter & Gamble Director Rajesh Subramaniam was awarded 1,475 shares of common stock as Restricted Stock Units, increasing his beneficial ownership.
Summary
- Rajesh Subramaniam, a Director of Procter & Gamble Co, acquired 1,475 shares of common stock.
- The acquisition occurred on October 14, 2025, at a price of $0 per share.
- These shares were awarded as Restricted Stock Units under The Procter & Gamble 2019 Stock and Incentive Compensation Plan.
- His beneficial ownership after this transaction is 6,149.8264 shares.
- The total beneficial ownership includes a grant of dividend equivalents also in the form of Restricted Stock Units.
- The transaction was made pursuant to a Rule 10b5-1(c) plan.
Sentiment
Score: 7
Explanation: The filing indicates a routine equity award to a director, aligning management interests with shareholders. This is generally a positive signal for corporate governance and executive retention, though not a direct indicator of operational performance.
Positives
- Director Rajesh Subramaniam received an award of 1,475 shares, indicating continued alignment of management interests with shareholders.
- The award is part of The Procter & Gamble 2019 Stock and Incentive Compensation Plan, a standard practice for executive compensation.
- The increase in beneficial ownership to 6,149.8264 shares demonstrates a higher stake in the company for the director.
Future Outlook
NA
Industry Context
This is a routine insider transaction related to executive compensation, common across all industries for publicly traded companies. It reflects standard practices for aligning executive incentives with company performance.
Comparison to Industry Standards
- Executive equity compensation, particularly through Restricted Stock Units (RSUs), is a standard practice in large consumer goods companies like Procter & Gamble.
- This compensation structure is comparable to those at companies such as Unilever, Kimberly-Clark, or Colgate-Palmolive.
- The grant of RSUs at a $0 price is typical for awards under incentive plans, reflecting a compensation component rather than a market purchase.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Plan Utilization | Award of Restricted Stock Units under The Procter & Gamble 2019 Stock and Incentive Compensation Plan. | 10/14/2025 | Reinforces alignment of director's interests with long-term shareholder value through equity-based compensation. |
Stakeholder Impact
- Shareholders: Positive, as it aligns director incentives with shareholder value through equity ownership.
- Management: Director's compensation package is enhanced, potentially increasing retention and motivation.
Key Dates
| Date | Description |
|---|---|
| 10/14/2025 | Date of transaction where Rajesh Subramaniam acquired common stock. |
| 10/15/2025 | Date the Form 4 was signed by the attorney-in-fact for Rajesh Subramaniam. |
Recommendation
holdThis Form 4 filing details a routine equity compensation award to a director, which is a standard practice for aligning management incentives with shareholder interests. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell the stock.
Keywords
Procter & Gamble, PG, Rajesh Subramaniam, Form 4, Insider Trading, Stock Award, Restricted Stock Units, Director Compensation, Equity Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.